These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 21368603

  • 1. A comparative study of F-18 FDG PET and 201Tl scintigraphy for detection of primary malignant bone and soft-tissue tumors.
    Yamamoto Y, Kawaguchi Y, Kawase Y, Maeda Y, Nishiyama Y.
    Clin Nucl Med; 2011 Apr; 36(4):290-4. PubMed ID: 21368603
    [Abstract] [Full Text] [Related]

  • 2. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH.
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [Abstract] [Full Text] [Related]

  • 3. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
    Tian M, Zhang H, Oriuchi N, Higuchi T, Endo K.
    Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL, Etchebehere M, Santos AO, Kalaf G, Pacheco EB, Amstalden EM, Etchebehere EC.
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
    Hamada K, Tomita Y, Ueda T, Enomoto K, Kakunaga S, Myoui A, Higuchi I, Yoshikawa H, Hatazawa J.
    Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
    [Abstract] [Full Text] [Related]

  • 6. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules.
    Higashi K, Ueda Y, Sakuma T, Seki H, Oguchi M, Taniguchi M, Taki S, Tonami H, Katsuda S, Yamamoto I.
    J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
    Miwa S, Mochizuki T, Yamamoto N, Shirai T, Hayashi K, Takeuchi A, Inatani H, Igarashi K, Higuchi T, Abe K, Taniguchi Y, Aiba H, Ikeda H, Tsuchiya H.
    Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic value of TI-201 and three-phase bone scintigraphy for bone and soft-tissue tumors.
    Nishiyama Y, Yamamoto Y, Toyama Y, Satoh K, Ohkawa M, Tanabe M.
    Clin Nucl Med; 2000 Mar; 25(3):200-5. PubMed ID: 10698418
    [Abstract] [Full Text] [Related]

  • 9. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
    Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN.
    Clin Cancer Res; 2008 May 15; 14(10):2970-7. PubMed ID: 18445694
    [Abstract] [Full Text] [Related]

  • 10. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R, Kido S, Suga K, Hirano Y, Tachibana R, Muramatsu K, Chagawa K, Tanaka S.
    Ann Nucl Med; 2014 Nov 15; 28(9):926-35. PubMed ID: 25107363
    [Abstract] [Full Text] [Related]

  • 11. Clinical significance of thallium-201 scintigraphy in bone and soft tissue tumors.
    Goto Y, Ihara K, Kawauchi S, Ohi R, Sasaki K, Kawai S.
    J Orthop Sci; 2002 Nov 15; 7(3):304-12. PubMed ID: 12077654
    [Abstract] [Full Text] [Related]

  • 12. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
    Yanagawa T, Saito K, Kiyohara H, Ohno T, Nakano T, Takagishi K.
    Radiat Oncol; 2015 Dec 21; 10():259. PubMed ID: 26691334
    [Abstract] [Full Text] [Related]

  • 13. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ.
    J Nucl Med; 2014 Feb 21; 55(2):191-7. PubMed ID: 24309383
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
    Zhang H, Tian M, Oriuchi N, Higuchi T, Watanabe H, Aoki J, Tanada S, Endo K.
    Nucl Med Commun; 2003 Mar 21; 24(3):273-9. PubMed ID: 12612468
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y, Tamaki N.
    J Nucl Med; 2001 Mar 21; 42(3):414-9. PubMed ID: 11337516
    [Abstract] [Full Text] [Related]

  • 19. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R, Su M, Tian Y, Li F, Li L, Kuang A, Zeng J.
    Skeletal Radiol; 2009 May 21; 38(5):451-8. PubMed ID: 19205695
    [Abstract] [Full Text] [Related]

  • 20. Assessment of chemosensitivity in patients with malignant bone and soft tissue tumors using thallium-201 scintigraphy and doxorubicin binding assay.
    Murata H, Kusuzaki K, Takeshita H, Hirata M, Hashiguchi S, Emoto K, Ashihara T, Hirasawa Y.
    Anticancer Res; 2000 May 21; 20(5C):3967-70. PubMed ID: 11268485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.